{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:04:31Z","timestamp":1760058271502,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Introduction: About one in four people show an immunological reaction to an infection with Mycobacterium tuberculosis, which can remain latent or lead to active forms of the disease. Psoriasis is a chronic, immune-mediated skin disease that can be associated with numerous comorbidities. Biologic therapies have revolutionized psoriasis treatment but carry the risk of reactivating latent tuberculosis infection. However, the link between tuberculosis as a triggering factor for the onset of psoriasis remains unknown. Clinical Case: We present the case of a patient initially diagnosed with secondary pulmonary tuberculosis, who, two months after the diagnosis, showed a remarkable clinical evolution by developing lesions consistent with vulgar psoriasis, necessitating a multidisciplinary treatment approach. Discussions: This unique case highlights the shared immune mechanism of these diseases, particularly involving TNF-\u03b1, IL-17, and CD4+ T cells. Conclusions: The coexistence of these conditions raises critical questions about the interplay between infectious and autoimmune diseases and the impact of genetic susceptibility.<\/jats:p>","DOI":"10.3390\/clinpract15040071","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:36:49Z","timestamp":1743169009000},"page":"71","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vulgar Psoriasis Triggered by Active Pulmonary Tuberculosis: A Case Report and Literature Review Highlighting Immunological Interactions and Genetic Susceptibility"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6835-2285","authenticated-orcid":false,"given":"Alexandra-Cristiana","family":"Gache","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u2018Ovidius\u2019 University of Constanta, 1 University Alley, 900470 Constanta, Romania"},{"name":"County Emergency Clinical Hospital, 145 Tomis Boulevard, 900591 Constanta, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra-Florentina","family":"B\u00eelb\u0103","sequence":"additional","affiliation":[{"name":"Dermatology Clinic of County Emergency Clinical Hospital, 126 \u0218tefan Cel Mare Street, 900178 Constanta, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea-Raluca","family":"Pricop","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u2018Ovidius\u2019 University of Constanta, 1 University Alley, 900470 Constanta, Romania"},{"name":"Dermatology Clinic of County Emergency Clinical Hospital, 126 \u0218tefan Cel Mare Street, 900178 Constanta, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-0038","authenticated-orcid":false,"given":"Elena","family":"Dante\u0219","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u2018Ovidius\u2019 University of Constanta, 1 University Alley, 900470 Constanta, Romania"},{"name":"Clinical Hospital of Pneumophtisiology, 40 Sentinelei Street, 900002 Constanta, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"220166","DOI":"10.1183\/20734735.0166-2022","article-title":"Tuberculosis: Current Challenges and Beyond","volume":"19","author":"Ghodousi","year":"2023","journal-title":"Breathe"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"210149","DOI":"10.1183\/20734735.0149-2021","article-title":"New Developments in Tuberculosis Diagnosis and Treatment","volume":"18","author":"Gill","year":"2022","journal-title":"Breathe"},{"key":"ref_3","first-page":"1449","article-title":"Genetics of psoriasis and psoriatic arthritis: Update and future direction","volume":"35","author":"Duffin","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A Brief Overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_5","unstructured":"World Health Organization (2016). Global Report on Psoriasis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1080\/09546634.2022.2062280","article-title":"Lack of Reactivation of Tuberculosis in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Latent Tuberculosis Infection","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijdvl.IJDVL_791_18","article-title":"Risk of Tuberculosis with Anti-Tumor Necrosis Factor-Alpha Therapy in Patients with Psoriasis and Psoriatic Arthritis in Indian Population","volume":"86","author":"Sarkar","year":"2020","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_8","first-page":"13030","article-title":"Risk of Tuberculosis with the Use of Anti-TNF Medications in Psoriasis: Incidence, Screening and Management","volume":"20","author":"Kasiraman","year":"2014","journal-title":"Dermatol. Online J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of Tuberculosis","volume":"19","author":"Sia","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01023-15","DOI":"10.1128\/mBio.01023-15","article-title":"Targeting Mycobacterium Tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines","volume":"7","author":"Olsen","year":"2016","journal-title":"mBio"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Society for Investigative Dermatology (2017). Society for Investigative Dermatology 2016 Board of Directors Meeting Minutes. J. Investig. Dermatol., 137, 2655\u20132662.","DOI":"10.1016\/j.jid.2017.10.003"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5455\/msm.2022.33.40-43","article-title":"Serum Levels of Tumor Necrosis Factor\u2014Alpha in Patients with Psoriasis","volume":"34","year":"2022","journal-title":"Mater. Socio-Medica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1084\/jem.20100265","article-title":"Pathological Role of Interleukin 17 in Mice Subjected to Repeated BCG Vaccination after Infection with Mycobacterium Tuberculosis","volume":"207","author":"Cruz","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00403-007-0775-4","article-title":"The Role of Dendritic Cells in the Immunopathogenesis of Psoriasis","volume":"299","author":"Jariwala","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","article-title":"Immunopathogenic Mechanisms in Psoriasis","volume":"135","author":"Gudjonsson","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.22159\/ijcpr.2023v15i1.2075","article-title":"PSORIASIFORM DRUG ERUPTION INDUCED BY ANTI-TUBERCULOSIS MEDICATION: A CASE REPORT","volume":"15","author":"Sindhu","year":"2023","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/00015555-0827","article-title":"Psoriasiform drug eruption induced by anti-tuberculosis medication: Potential role of plasma-cytoid dendritic cells","volume":"90","author":"Park","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1111\/ajd.14364","article-title":"Tuberculosis Reactivation Following Apremilast Therapy for Psoriasis: Time to Consider Routine TB Screening?","volume":"65","author":"Adams","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_21","unstructured":"European Medicines Agency (2024, December 19). Otezla: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-012-1214-8","article-title":"German S3-Guidelines on the Treatment of Psoriasis Vulgaris (Short Version)","volume":"304","author":"Nast","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s12325-024-02873-2","article-title":"Management of Psoriasis Patients with Serious Infectious Diseases","volume":"41","author":"Megna","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_24","first-page":"95","article-title":"Ustekinumab Treatment in Patients with Moderateto-Severe Psoriasis and Latent Tuberculosis Infection: A Study of 3 Case Reports","volume":"12","author":"Abdulwahhab","year":"2022","journal-title":"J. Cosmet. Dermatol. Sci. Appl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clindermatol.2007.11.006","article-title":"Systemic therapies for psoriasis: Methotrexate, retinoids, and cyclosporine","volume":"26","author":"Richard","year":"2008","journal-title":"Clin. Dermatol."},{"key":"ref_26","unstructured":"Zito, P.M., Patel, P., and Mazzoni, T. (2025, March 18). Acitretin, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519571\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.37349\/emd.2023.00026","article-title":"How should we do in the selection and follow-up of systemic conventional treatments in psoriasis?","volume":"1","author":"Akarsu","year":"2023","journal-title":"Explor. Musculoskelet. Dis."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/4\/71\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:33Z","timestamp":1760029473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/4\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["clinpract15040071"],"URL":"https:\/\/doi.org\/10.3390\/clinpract15040071","relation":{},"ISSN":["2039-7283"],"issn-type":[{"type":"electronic","value":"2039-7283"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}